Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors

1. A compound of the following Formula VI:

Wherein M is COX with X is OR′ and R′ is H;

D is (CH 2 ) n″ wherein n″ is 2;

Q is (CH 2 ) n′″ wherein n′″ is 0 or 1;

R 5 is H or C 1 -C 6 alkyl; and

R 6 is —CHR 7 —W, wherein R 7 is H or C 1 -C 6 alkyl; W is phenyl.

2. The compound of claim 1 , wherein R 6 is —CHR 7 —W, wherein R 7 is H or methyl; W is unfused phenyl substituted with a group selected from H, halogen, —OCF3, and —CF3.

3. The compound as claimed in claim 1 , wherein the compound exhibits a Ki of about 50 μM or less in a standard EP2 receptor binding assay.

4. The compound as claimed in claim 1 , wherein the compound exhibits a K i of about 10 μM or less in a standard EP2 receptor binding assay.

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds as claimed in claim 1 .

6. The pharmaceutical composition as claimed in claim 5 , wherein the compound is packaged together with instructions for use of the compound to treat preterm labor, dysmenorrhea, asthma, hypertension, infertility or a fertility disorder, sexual dysfunction, undesired blood cloning, a destructive bone disease or disorder, preeclampsia or eclampsia, or an cosinophil disorder.

7. A compound selected from the group consisting of:

4-[2-(2-(3-hydroxyoctyl)-5-oxopyrazolidin-1-yl)ethyl]benzoic acid;

4-{2-[2-(4-hydroxynon-2-ynyl)-5-oxopyrazolidin-1-yl]ethyl}benzoic acid;

4-{2-[2-(4-hydroxynonyl)-5-oxopyrazolidin-1-yl]ethyl }benzoic acid;

4-(2-{2-[(2Z)-4-hydroxynon-2-enyl]-5-oxopyrazolidin-1-yl)ethyl)benzoic acid;

4-(2-{2-[(2E)-4-hydroxynon-2-enyl]-5-oxopyrazolidin-1-yl)ethyl)benzoic acid;

4-{2-[2-(4-hydroxyoctyl)-5-oxopyrazolidin-1-yl]ethyl) benzoic acid;

4-{2-[2-(4-hydroxy-6-methylheptyl)-5-oxopyrazolidin-1-yl]ethyl}benzoic acid;

4-{2-[2-(4-hydroxy-5-methyloctyl)-5-oxopyrazolidin-1-yl)ethyl}benzoic acid;

4-{2-[2-(4-ethyl-4-hydroxyoctyl)-5-oxopyrazolidin-1-yl]ethyl}benzoic acid;

4-{2-[2-(4-hydroxy-4-methylheptyl)-5-oxopyrazolidin-1-yl]ethyl}benzoic acid;

4-(2-[2-(4-hydroxy-4,7-dimethyloctyl)-5-oxopyrazolidin-1-yl]ethyl}benzoic acid;

4-{2-[2-(3 -hydroxy-5-methylhexyl)-5-oxopyrazolidin-1-yl]ethyl) benzoic acid;

4-{2-[2-(3 -cyclobutyl-3-hydroxypropyl)-5-oxopyrazolidin-1-yl]ethyl}benzoic acid;

4-{2-[2-((4S)-hydroxynonyl)-5-oxopyrazolidin-1-yl]ethyl}benzoic acid;

4-{2-[2-((4R)-hydroxynonyl)-5-oxopyrazolidin-1-yl]ethyl }benzoic acid;

4-[2-(2-{4-[1-(cyclopropylmethyl)cyclobutyl]-4-hydroxybutyl)-5-oxopyrazolidin-1-yl)ethyl]benzoic acid;

4-(2-{2-[4-(1-ethylcyclobutyl)-4-hydroxybutyl]-5-oxopyrazolidin-1-yl)ethyl)benzoic acid; 4-(2-{2-[3-hydroxy-4-(3-methylphenyl)butyl]-5-oxopyrazolidin-1-yl)ethyl)benzoic acid; 4-{2-[2-(3-hydroxy-4-phenylbutyl)-5-oxopyrazolidin-1-yl]ethyl}benzoic acid;

4-(2-{2-[4-(3-iodophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl}ethyl) benzoic acid;

4-(2-{2-[4-(3-bromophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl)ethyl)benzoic acid;

4-[2-(2-{3-hydroxy-4-[3-(trifluoromethoxy)phenyl]butyl)-5-oxopyrazolidin-1-yl) ethyl]benzoic acid;

4-(2-{2-[4-(3-fluorophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl }ethyl) benzoic acid;

4-[2-(2-{3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrazolidin-1-yl) ethyl]benzoicacid;

4-(2-{2-[(3S, 4S)-3-hydroxy-4-phenylpentyl]-5-oxopyrazolidin-1-yl}ethyl) benzoic acid;

4-(2-(2-[4-(1,3-benzodioxol-5-yl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl}ethyl) benzoicacid;

4-(2-{2-[4-(3-chlorophenyl)-3-hydroxybutyl]-5-oxopyrazolidin-1-yl}ethyl) benzoic acid;

4-(2-{2-[(4R)-3-hydroxy-4-phenylpentyl]-5-oxopyrazolidin-1-yl)ethyl)benzoic acid;

and pharmaceutically acceptable salts thereof.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds as claimed in claim 7 .

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds as claimed in claim 2 .